Oncology and
‍
Rare Tumors

Hybrid Drugs for Cancer & Rare Tumors

Medication can treat the biology. It rarely addresses what people live through alongside it - the pain and stiffness, the fatigue, the fear and uncertainty, the strain on daily life. Remepy is developing investigational Hybrid Drugs that pair targeted therapies with an app-delivered therapeutic protocol, designed to support people through treatment for cancer and rare tumors.
‍
Want to learn more and partner with us?

RARE TUMORS
<200K

people in the US - the threshold that defines a rare disease

In the US, a disease is considered rare when it affects fewer than 200,000 people. Many rare tumors are non-malignant, but they can still be chronic and disruptive - bringing pain, stiffness, and reduced mobility that shape daily life for years. People living with them often wait longer for a diagnosis, have fewer treatment options, and find little guidance tailored to their condition, including how to stay active and manage symptoms while on treatment.

Rare Cancers
1 in 5

US cancer diagnoses are rare cancers

Rare cancers are individually uncommon, but together they account for about one in five cancer diagnoses in the US. As with rare tumors more broadly, people living with them often face a longer road to diagnosis, fewer treatment options, and little guidance built around their condition.

One Treatment, Two Layers

Our Hybrid Drugs for rare tumors are designed to complement the drug's mechanism of action -
and support the person taking it.

Each program pairs a targeted therapy with a proprietary digital protocol. The protocol is built around how the drug is given - whether for chronic, ongoing treatment or for a set treatment period - and adapts to each person's starting point and progress.

  • 01 The Drug

    A targeted therapy that acts on the biology of the tumor.

  • 02 The Digital Layer

    An app-delivered protocol of evidence-based physical, psychological, and behavioral interventions - such as guided rehabilitation and pain self-management - tailored to the treatment.

The Outcome

By addressing the burden that comes with treatment and combining the drug with a daily protocol of digital interventions, we aim to help people regain function, manage pain, and stay on their therapy - and we are studying whether this integrated approach can lead to better overall outcomes.

What We're Designing For

  • Restore Movement & Function

    Guided, adaptive physical rehabilitation for mobility, strength, and endurance - offered as support and tailored to each person's capacity.

  • Manage Pain

    Pain education and self-management skills, developed with pain medicine specialists and focused on function and daily life.

  • Ease Distress

    Tools grounded in cognitive behavioral therapy (CBT), acceptance and commitment therapy (ACT), and mindfulness to help manage anxiety, fear, and uncertainty.

  • Support Daily Treatment

    Medication reminders, guidance through each stage of treatment, and practical support for nutrition, sleep, and daily routines.

Built on Our Platform Science

Our oncology Hybrid Drug programs use the same scientific foundation as our other Hybrid Drug programs across a range of therapeutic areas: a single treatment in which the drug and the digital protocol are designed together. The goal is to address what matters to patients and their clinicians. Learn about the science.

  • Built with Clinicians & Patients

    Developed with oncologists, rehabilitation and pain specialists, and informed by people living with rare tumors.

  • Aligned with Each Stage of Treatment

    Designed around each stage of treatment, so support fits what people need as their therapy progresses.

  • Adaptive
    by Design

    Adapting to how each individual responds, keeping them in control at every step.

Build it with us.

We're working with fertility clinics, menopause specialists, researchers, and pharma partners to shape these programs. If you'd like to collaborate, or follow our progress, get in touch.